drugset
drugset / Trial / NCT04179019

Calcium Channel Blockade in Primary Aldosteronism

NCT04179019 ↗

Phase 2 Completed 15 enrolled Brigham and Women's Hospital University of Michigan · collab
NaSingle-groupOpen-labelTreatment

Summary

This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.

Timeline

Start
2020-09-01
Primary completion
2023-12-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg —

Indications

primary aldosteronism